Condition
Penile Neoplasms
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed3
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06638931Phase 2Recruiting
Agnostic Therapy in Rare Solid Tumors
NCT05578820Phase 1Completed
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
NCT03012581Phase 2Completed
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT03774901Phase 2Unknown
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
NCT01728233Phase 2CompletedPrimary
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis
Showing all 5 trials